Sophia Genetics(SOPH) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [28] - Full year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [32] - Gross profit for Q4 was $14.7 million, up 21% from $12.1 million in the prior year [28] - Adjusted gross margin for the full year 2025 was 74.2%, an increase of 140 basis points from 72.8% in 2024 [34] - Annualized revenue churn was less than 1% for 2025, with net dollar retention increasing to 115% [33] Business Line Data and Key Metrics Changes - Clinical revenue excluding biopharma grew 31% year-over-year in Q4 2025 [14] - Hemonc volumes grew 27% year-over-year in Q4, indicating strong performance in hemato-oncology testing [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [17] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4, with clinical revenue up 35% year-over-year [15] - North America saw analysis volumes grow 45% year-over-year in Q4 [15] - Asia Pacific revenue grew 44% in Q4, driven by India and Australia [16] - Latin America experienced a recovery with 49% revenue growth in Q4, particularly in Mexico and Brazil [16] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives to modernize its platform [8] - SOPHiA DDM Digital Twins were launched to create AI-driven virtual representations of patients, enhancing treatment decision-making [11] - The company aims to leverage partnerships, such as with MD Anderson, to co-develop new tests and applications [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [42] - The company expects full year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [38] - Adjusted EBITDA loss is projected to be between $29 million and $32 million for 2026, an improvement from 2025 [39] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [7] - The platform's scalability has improved significantly, allowing for faster and more cost-efficient genomic analysis [9] Q&A Session Summary Question: Contributions from key growth drivers for 2026 - Management highlighted strong performance in Q4 with 31% revenue growth and emphasized the ramping of MSK-ACCESS as a key driver for growth [46][47] Question: Net dollar retention and cross-selling strength - Management noted that the re-acceleration in net dollar retention to 115% reflects the platform's stickiness and the ability to expand within accounts [51][52] Question: Potential annual contribution from new pharma contracts - Management indicated that while the pharma business takes time to ramp, they expect a positive contribution in 2026, with ongoing strategic steps to enhance growth [58][60] Question: Expansion potential with new health systems - Management expressed optimism about the potential for significant growth with the two large health systems, indicating opportunities for expansion beyond initial applications [62][65] Question: Volume price mix for 2026 guidance - Management expects ASPs to increase due to higher-priced tests being sold, while also anticipating volume growth in regions with lower ASPs [70][71] Question: New CEO's approach and potential changes - The new CEO emphasized a focus on scaling the business and unlocking the full value of the platform while maintaining a disciplined investment strategy [73][75]